HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) Prophylaxis
Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis
Date Reviewed: July 26, 2014
NQF 0405 CMS 160 NQF Endorsed
National Committee for Quality Assurance
Clinical Topic Area
ACP supports NQF 0405: “HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) Prophylaxis” because it aligns with current US Department of Health and Human Services guidelines for the prevention of opportunistic infections in those diagnosed HIV/AIDS.